NO-naproxen (AstraZeneca).
NO-naproxen, consisting of the NSAID naproxen linked to a nitric oxide (NO) moiety, is under development by AstraZeneca plc, under license from NicOx SA, for the potential treatment of acute/chronic pain.
Animals↗
Biomedical subjects
Nat Monck
Publications and source records attributed to Nat Monck.
EN-3231. Endo Pharmaceuticals.
Endo (which acquired Algos in July 2000) has developed EN-3231, a combination of morphine and dextromethorphan, for the treatment of moderate-to-severe chronic pain. In October 1998, the FDA accepted for filing the company's NDA submission on EN-3231, which was submitted in August 1998. However, in August 1999, Algos received a 'non-approvable' letter from the FDA for EN-3231. In September 2000, the company met with the FDA to discuss what information the FDA required in order to approve EN-3231. The FDA requested a second pivotal trial, which Endo initiated promptly. Endo hoped to file its supplement to the NDA during 2002.
Analgesics, Opioid↗